425: BioNTech to Acquire CureVac, Bolstering mRNA Oncology Pipeline

BioNTech SE announces a tender offer to acquire all outstanding shares of CureVac N.V., aiming to expand its mRNA oncology capabilities and diversify its product pipeline.

Summary

• BioNTech SE is launching a tender offer to acquire all issued ordinary shares of CureVac N.V. (CVAC) in exchange for newly registered BioNTech American Depositary Shares (ADSs).
• The exchange ratio is determined by dividing $5.4641 by the 10-day volume-weighted average price (VWAP) of BioNTech ADSs, subject to collar adjustments: 0.04318 if BioNTech ADS VWAP >= $126.55, and 0.06476 if BioNTech ADS VWAP <= $84.37.
• The offer commences on October 21, 2025, and is initially open until December 3, 2025.
• Key conditions for the offer include a minimum tender of 80% of CureVac's share capital (reducible to 75%) and necessary antitrust and regulatory approvals, which have largely been obtained for non-U.S. jurisdictions.
• Shareholders representing approximately 57% of CureVac's shares (dievini Hopp BioTech, KfW, Glaxo Group Limited, and CureVac board members) have agreed to tender their shares.
• The acquisition is expected to cost BioNTech approximately €17.5 million in transaction expenses.
• BioNTech reported a net loss of €802.4 million for the six months ended June 30, 2025, an improvement from a €1,122.9 million net loss in the prior-year period.
• CureVac reported a net loss of €111,644 thousand for the six months ended June 30, 2025, an improvement from a €143,096 thousand net loss in the prior-year period.
• BioNTech expects full-year 2025 revenues between €1.7 billion and €2.2 billion, and a net loss for the year.
• The company anticipates significant R&D expenses of €2.6 billion to €2.8 billion and sales, general, and administrative expenses of €650.0 million to €750.0 million for FY2025.
• BioNTech's cash and cash equivalents stood at €10,269.5 million as of June 30, 2025.

Sentiment

Score: 6

Explanation: The acquisition of CureVac and the BMS collaboration provide strong strategic positives and significant capital inflow, which are crucial for BioNTech's long-term oncology pipeline. However, the continued net losses, negative operating cash flow, and ongoing litigation present notable financial and operational challenges, balancing the overall sentiment to moderately positive.

Positives

• The acquisition of CureVac is expected to provide significant strategic benefits, including furthering BioNTech's mRNA strategy in oncology and expanding its capabilities in target discovery, production, mRNA design, and delivery formulations.
• The transaction complements BioNTech's recent acquisitions in other oncology pillars, such as immunomodulators and antibody-drug conjugates.
• BioNTech's operating loss decreased by 30% to €1,035.2 million for the six months ended June 30, 2025, compared to €1,473.4 million in the same period of 2024, indicating an improving operational trend.
• Net loss for BioNTech decreased by 29% to €802.4 million for the six months ended June 30, 2025, compared to €1,122.9 million in the same period of 2024.
• BioNTech's COVID-19 vaccine revenues increased by 46% to €286.3 million for the six months ended June 30, 2025, compared to €196.1 million in the prior-year period, driven by higher dose volumes.
• The company maintains a strong balance sheet with approximately €16.0 billion in total cash, cash equivalents, and security investments as of June 30, 2025.
• BioNTech secured a global co-development and co-commercialization agreement with Bristol Myers Squibb (BMS) for BNT327, including a $1.5 billion upfront payment and $2.0 billion in non-contingent anniversary payments through 2028, plus up to $7.6 billion in potential milestones.
• Non-U.S. antitrust approvals for the CureVac acquisition have been obtained as of October 14, 2025, and EU FSR Regulation clearance was fulfilled on October 10, 2025, reducing regulatory uncertainty.
• BioNTech maintains its 'Prime' status from ISS ESG and improved its overall rating from Bto B in the Corporate Rating 2024, reflecting strong ESG performance.
• The company's near-term science-based emission reduction targets (42% reduction in Scope 1 and 2 GHG emissions by 2030 from a 2021 base year) have been validated by the Science Based Targets initiative (SBTi).

Negatives

• BioNTech expects to report a net loss for the full financial year 2025, continuing a trend of losses from 2024.
• BioNTech's net cash flows from operating activities for the six months ended June 30, 2025, were negative €634.2 million, a significant decrease from a positive €1,309.9 million in the prior-year period.
• CureVac's revenue for the six months ended June 30, 2025, significantly decreased to €2,138 thousand from €26,809 thousand in the prior-year period.
• The acquisition of CureVac will result in dilution for existing BioNTech shareholders, with their shareholding percentage decreasing by approximately 4.0% to 5.9%.
• CureVac shareholders who do not tender their shares in the offer may be subject to Dutch dividend withholding tax on the cancellation consideration, potentially resulting in a lower after-tax return.
• BioNTech's operating profit/loss shifted from a profit of €690.4 million in 2023 to a loss of €1,314.3 million in 2024, primarily due to decreased COVID-19 vaccine sales and increased expenses from contractual disputes and R&D.
• The company incurred significant expenses from inventory write-downs and scrapings related to COVID-19 vaccines, amounting to €125.8 million in 2024 and €64.3 million for the six months ended June 30, 2025.
• BioNTech faces ongoing and complex patent litigation with Moderna, Arbutus/Genevant, GSK, and Promosome, which could result in substantial costs and divert management attention.
• The company is subject to a securities class action lawsuit (Ladewig v. BioNTech SE), although the operative complaint was dismissed, plaintiffs may appeal.
• The regulatory approval pathway for mRNA-based therapies is uncertain, complex, expensive, and lengthy, posing risks to BioNTech's product candidates.

Risks

• Demand for BioNTech's COVID-19 vaccine is expected to continue decreasing, impacting revenues heavily reliant on its sales.
• Uncertainty in COVID-19 vaccine demand and supply targeting may lead to significant inventory write-downs and contract manufacturing order cancellations.
• Successful commercialization of product candidates depends on governmental and private payor coverage and adequate reimbursement levels; failure to obtain these could limit marketability and revenue generation.
• Operating results may fluctuate significantly, making future results difficult to predict, and falling below expectations could cause ADS price decline.
• Difficulties in developing and expanding the company, including managing acquisitions like Biotheus, could disrupt operations.
• Business is dependent on successful development, regulatory approval, and commercialization of product candidates; failure in any of these stages would significantly harm the business.
• Clinical development is lengthy, expensive, and uncertain, with potential for delays, increased costs, or difficulty recruiting patients.
• Reliance on information technology systems exposes the company to security breaches, data loss, and other disruptions, compromising sensitive information and exposing to liability.
• Manufacturing of novel technology-based products (COVID-19 vaccine, product candidates) is complex and difficult, potentially leading to delays or supply interruptions.
• Reliance on third parties for preclinical studies, clinical trials, and manufacturing poses risks if they fail to perform duties, comply with regulations, or meet deadlines.
• Inadequate intellectual property protection (patents, trade secrets) could hinder competitive effectiveness, with ongoing patent litigation (e.g., CureVac, Moderna, Arbutus, Genevant, GSK, Promosome) posing significant risks.
• Regulatory authorities may disagree with regulatory plans, leading to failure or delays in obtaining product candidate approvals.
• Approved products are subject to continuing regulatory oversight and ongoing obligations, with potential penalties for non-compliance or unanticipated problems.
• Government policies (manufacturing, export controls, tariffs) and negative public perception regarding vaccines and mRNA-based therapeutics could severely impact manufacturing and sales.
• Significant competition from other vaccine makers and pharmaceutical companies could lead to loss of market share or make new products obsolete.
• Temperature sensitivity of products and supply chain challenges could lead to loss or damage, making products less competitive.
• Market opportunities for some product candidates may be small due to disease rarity or limited patient populations, hindering profitability without additional indications.
• Achieving or maintaining profitability depends on penetrating global markets, which involves additional regulatory burdens and international operational risks (e.g., currency fluctuations, trade restrictions).
• Product candidates may not gain market acceptance among medical community, patients, and payors, even if approved.
• Advancement of healthcare reform legislation could increase difficulty and cost of obtaining marketing approval and commercializing products, and adversely affect pricing.
• Drug marketing and reimbursement regulations in the EU and elsewhere may materially affect ability to market and receive coverage.
• Amount and use of net operating losses and R&D credits may be limited, and tax audits or changes in tax law could lead to additional liabilities.
• Obligation to withhold wage tax and social security contributions if contract service providers are deemed employees, with late payments subject to penalties.
• Need for substantial additional financing; failure to obtain capital could delay, limit, reduce, or terminate product development or commercialization.
• International trade obligations (customs value, tariff classification) and late payments to customs authorities may result in penalties.
• As a foreign private issuer, BioNTech is exempt from certain U.S. securities and Nasdaq rules, limiting information available to ADS holders and potentially making ADSs less attractive.
• Insurance policies are expensive and may not cover all business risks, leaving the company exposed to significant uninsured liabilities.
• Adverse developments affecting financial institutions could adversely affect operations and liquidity.
• Issues in the development and use of AI, combined with an uncertain regulatory environment, may result in reputational harm, liability, or other adverse consequences.
• Failure to effectively monitor and respond to ESG matters may impose unexpected costs or result in reputational harm.
• Certain product candidates are uniquely manufactured for each patient, posing production difficulties, especially with scaling manufacturing capabilities and maintaining chain of identity.
• Regulatory and operational risks associated with physical and digital infrastructure at manufacturing facilities, including potential malfunctions or system failures.
• Failure to comply with environmental, health, and safety laws and regulations could lead to fines or penalties.
• Governmental investigations and inquiries (e.g., U.S. Senate Homeland Security Committee) may adversely affect business, financial condition, and results of operations.
• Exposure to federal and state healthcare fraud and abuse laws, false claims laws, and other healthcare laws, with potential for substantial penalties for non-compliance.
• A third-party investigational product candidate used in combination with BioNTech's products may fail to obtain regulatory approval, delaying commercialization.
• The regulatory landscape for product candidates, especially gene and cell therapies, is uncertain, with evolving requirements potentially leading to delays or increased costs.
• Inability to obtain regulatory approval under international requirements would delay commercialization and impact revenue potential.
• The pendency of the CureVac acquisition could adversely affect the business and operations of both BioNTech and CureVac, including potential delays in decisions by counterparties and employee uncertainty.
• Counterparties to CureVac's significant agreements may exercise contractual rights (e.g., termination) due to the acquisition.
• Shareholder litigation against BioNTech and CureVac related to the transaction could result in injunctions or damages.
• The need to implement share capital increases for the offer will result in an extended settlement period, and tendering CureVac shareholders will not receive interest for this delay.
• Volatility in BioNTech ADS market price may continue due to various factors, including market perception of the acquisition and general economic conditions.
• Acquisitions, joint ventures, and collaborations may increase capital requirements, dilute shareholders, incur debt, or assume contingent liabilities, and expected benefits may not be realized.

Future Outlook

BioNTech does not expect to report a positive net income for the full financial year 2025. The company forecasts revenues between €1.7 billion and €2.2 billion, research and development expenses between €2.6 billion and €2.8 billion, and sales, general, and administrative expenses between €650.0 million and €750.0 million for FY2025. BioNTech aims to launch its first oncology product as early as 2026 and expects to receive a $1.5 billion upfront payment from BMS in Q3 2025, with an additional $2.0 billion in non-contingent anniversary payments through 2028, and up to $7.6 billion in potential development, regulatory, and commercial milestones.

Management Comments

• BioNTech's boards believe the acquisition of CureVac will have significant potential strategic benefits, including furthering BioNTech's mRNA strategy to develop, manufacture, and commercialize mRNA-based medicines in oncology.
• The acquisition is expected to expand BioNTech's capabilities in target discovery, production, mRNA design, and delivery formulations, complementing recent acquisitions in immunomodulators and antibody-drug conjugates.
• BioNTech plans to undertake a detailed strategic review of the CureVac business post-acquisition to formulate an appropriate detailed integration plan.
• BioNTech recognizes the importance of research and development in CureVac's business and intends to maintain investment in R&D in Germany.
• BioNTech plans to comply with CureVac's current consultation obligations towards existing employee representative bodies and existing works agreements post-acquisition.
• The headquarters of the combined business will remain in Mainz, Germany, with a CureVac presence maintained in Tübingen, Germany, including its research and manufacturing site.
• BioNTech intends to leverage the combined businesses' global presence to consolidate minor administrative offices where feasible to reduce property expenses and enable closer collaboration.
• BioNTech does not currently have any plans for material disinvestments or to cancel previously announced future investments or disinvestments.

Industry Context

The global market for cancer immunotherapies was estimated at $12.2 billion in 2024 and is projected to grow at a compound annual growth rate of 15% to approximately $31.3 billion by 2030. This growth is driven by increasing cancer prevalence, rising acceptance of immunotherapy, and advancements in targeted therapies. BioNTech's acquisition of CureVac, an mRNA therapeutics company, positions it to further capitalize on this trend by expanding its mRNA-based oncology platform and diversifying its pipeline beyond its successful COVID-19 vaccine, Comirnaty. The move reflects a broader industry shift towards advanced therapeutic modalities and strategic consolidation to gain competitive advantages in high-growth areas like oncology and infectious diseases.

Comparison to Industry Standards

• BioNTech's rapid development of Comirnaty, the first-ever approved mRNA-based product, demonstrates industry-leading speed from viral sampling to conditional approval (11 months), setting a high benchmark for vaccine development.
• The company's commitment to reducing absolute Scope 1 and Scope 2 greenhouse gas emissions by 42% by 2030 (from a 2021 base year) and ensuring 72% of suppliers have science-based targets by 2027 aligns with or exceeds many global pharmaceutical industry ESG standards, as evidenced by its 'Prime' status from ISS ESG and inclusion in the S&P Global Sustainability Yearbook 2025.
• BioNTech's extensive pipeline of 16 clinical oncology programs and six infectious disease programs, including multiple Phase 2 and Phase 3 trials, indicates a robust R&D investment strategy comparable to leading global biopharmaceutical companies like Moderna, Sanofi, and AstraZeneca, who are also active in mRNA and immunotherapy spaces.
• The shift from a pandemic to an endemic phase for COVID-19, impacting vaccine demand and revenues, is a trend observed across all major COVID-19 vaccine manufacturers, including competitors like Moderna, requiring adaptation of commercial strategies and product development (e.g., variant-adapted vaccines).

Management Changes

Corporate Governance

Legal Proceedings

• CureVac Proceedings: Ongoing lawsuits in Germany (Düsseldorf Regional Court) alleging Comirnaty's infringement of European patents (EP122, EP668, EP755) and German Utility Models (DE961, DE974, DE130). BioNTech has filed nullity and cancellation actions, with some patents found invalid at first instance or in preliminary opinions. Appeals are pending.
• CureVac Proceedings: U.S. District Court for the Eastern District of Virginia lawsuit by CureVac asserting infringement of U.S. patents, with a trial rescheduled for September 8, 2025.
• Moderna Proceedings: Multiple ongoing lawsuits in Germany, the U.K., U.S., Netherlands, Ireland, and Belgium alleging Comirnaty's infringement of European patents (EP949, EP565) and U.S. patents. Some patents have been found invalid or likely invalid in preliminary opinions or first-instance decisions, with appeals pending.
• Arbutus and Genevant Proceedings: Lawsuit in U.S. District Court for the District of New Jersey alleging infringement of U.S. patents related to lipid nanoparticle technology used in Comirnaty.
• Other Genevant Proceedings: Arbitration initiated by Genevant against BioNTech alleging breach of license and co-development agreement related to technology use outside prescribed fields and wrongful disclosure of confidential information.
• GlaxoSmithKline Proceedings: Lawsuits in U.S. District Court for the District of Delaware, High Court of Ireland, and Unified Patent Court (Hague Division) alleging Comirnaty's infringement of U.S. and European patents related to cationic lipids.
• Ladewig Proceedings: Securities class action complaint in U.S. District Court for the Southern District of New York alleging violations of Exchange Act by overstating demand for Comirnaty and failing to adapt inventory. The operative complaint was dismissed, but plaintiffs may appeal.

Related Party Transactions

• ATHOS KG, through AT Impf GmbH, holds de facto control over BioNTech (42.1% of ordinary shares), enabling it to influence shareholder resolutions.
• Transactions with entities controlled by ATHOS KG included purchases of goods and services (€0.2 million in 2024) and property and other assets (€62.5 million in 2022).
• Key management personnel (Management Board and Supervisory Board members) receive compensation, including fixed, short-term, and long-term incentives, and participate in share-based payment arrangements.
• Prof. Ugur Sahin, M.D. (CEO) and Prof. Özlem Türeci, M.D. (CMO) are married, and Prof. Sahin is the sole shareholder of Medine GmbH, which holds 16.7% of BioNTech's shares, creating a potential conflict of interest.
• Helmut Jeggle (Chair of Supervisory Board) holds functions and management positions at BioNTech's indirect controlling shareholders (ATHOS KG affiliates), constituting a potential conflict of interest.

Stakeholder Impact

• **Shareholders (BioNTech)**: Will experience dilution (4.0% to 5.9% decrease in ownership) due to the issuance of new ADSs for the CureVac acquisition. The strategic benefits of expanding the oncology pipeline and the significant capital raise from BMS could positively impact long-term value, but current net losses and litigation risks pose short-term concerns.
• **Shareholders (CureVac)**: Will exchange their shares for BioNTech ADSs, receiving a fixed-value consideration. Non-tendering shareholders may face Dutch dividend withholding tax, potentially reducing their after-tax return. The acquisition offers a clear exit strategy and integration into a larger, diversified biopharmaceutical company.
• **Employees (CureVac)**: BioNTech plans to comply with existing employment terms and benefits, and maintain a presence in Tübingen, Germany. However, capacity adjustments in manufacturing and administrative functions across the combined entity may lead to workforce reductions in certain areas (e.g., Marburg, Idar-Oberstein, North America).
• **Customers**: The acquisition aims to enhance BioNTech's capabilities in mRNA-based medicines, potentially leading to a broader range of innovative treatments for cancer and infectious diseases. Continued development of variant-adapted COVID-19 vaccines and equitable access initiatives (e.g., BioNTainer in Africa) benefit global public health.
• **Suppliers**: BioNTech's commitment to reducing Scope 3 emissions and engaging suppliers with science-based targets will impact its supply chain. The consolidation of administrative offices and manufacturing capacities may affect existing supplier relationships.
• **Creditors**: BioNTech's strong cash position and significant capital raise from BMS enhance its financial stability, potentially improving its creditworthiness. However, substantial R&D investments and ongoing litigation could impact future cash flows.

Next Steps

• BioNTech will continue to advance additional product candidates to late-stage development, aiming for its first oncology launch as early as 2026.
• The company plans to continue investing in the research and development of next-generation COVID-19 vaccines and COVID-19/influenza combination vaccines.
• BioNTech is preparing for the global commercial roll-out of a new variant-adapted COVID-19 vaccine for the 2025/2026 season, subject to regulatory approvals.
• BioNTech will continue to work with CEPI to establish RNA vaccine clinical and commercial-scale manufacturing capabilities at its facility in Kigali, Rwanda.
• The company plans to establish two new R&D centers in the U.K. and its U.K. headquarters in London, which will also accommodate its AI hub, with investments of up to €1 billion over the next ten years.
• BioNTech will continue to monitor the evolving epidemiology of COVID-19 and remain prepared to develop modified vaccine formulas as data support and regulatory agencies recommend.
• BioNTech will work with the FDA to address requests and assess next steps for the clinical hold on the malaria vaccine candidate BNT165b1.
• BioNTech and Pfizer are considering next steps for the wind-down and further advancement of the shingles program (BNT167) after both opted out of joint development.
• BioNTech plans to undertake a detailed strategic review of the CureVac business post-acquisition to formulate an appropriate detailed integration plan.
• The company will continue to vigorously defend itself in ongoing patent litigation and other legal proceedings.

Key Dates

Recommendation

The acquisition of CureVac and the substantial capital infusion from the BMS collaboration are strategically positive, significantly strengthening BioNTech's oncology pipeline and long-term growth prospects. However, the company continues to report net losses and negative operating cash flows, indicating ongoing financial challenges. The inherent risks of pharmaceutical development, intense competition, and extensive patent litigation create considerable uncertainty. While the long-term vision is compelling, the near-term financial performance and the complexities of integrating CureVac, coupled with the ongoing legal battles, suggest a 'hold' recommendation. Investors should monitor the execution of the integration, progress in the oncology pipeline, and the outcomes of key legal proceedings before considering a stronger position.

Keywords

mRNA, Oncology, Infectious Diseases, Vaccines, Immunotherapy, Acquisition, CureVac, BioNTech, Biotechnology, Pharmaceuticals, Clinical Trials, Regulatory Approval, COVID-19 Vaccine, Antibody-Drug Conjugates, CAR-T Therapy, Gene Therapy, Financial Results, Capital Raise, Patent Litigation, ESG